CHROMADEX CORP (CDXC) Stock Fundamental Analysis

NASDAQ:CDXC • US1710774076

7.87 USD
-0.07 (-0.88%)
At close: Mar 18, 2025
7.87 USD
0 (0%)
After Hours: 3/18/2025, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

Taking everything into account, CDXC scores 6 out of 10 in our fundamental rating. CDXC was compared to 58 industry peers in the Life Sciences Tools & Services industry. While CDXC has a great health rating, its profitability is only average at the moment. CDXC is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year CDXC was profitable.
  • CDXC had a positive operating cash flow in the past year.
  • In the past 5 years CDXC reported 4 times negative net income.
  • In multiple years CDXC reported negative operating cash flow during the last 5 years.
CDXC Yearly Net Income VS EBIT VS OCF VS FCFCDXC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

  • With an excellent Return On Assets value of 12.52%, CDXC belongs to the best of the industry, outperforming 90.91% of the companies in the same industry.
  • The Return On Equity of CDXC (18.55%) is better than 90.91% of its industry peers.
  • CDXC's Return On Invested Capital of 12.13% is amongst the best of the industry. CDXC outperforms 89.09% of its industry peers.
Industry RankSector Rank
ROA 12.52%
ROE 18.55%
ROIC 12.13%
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
CDXC Yearly ROA, ROE, ROICCDXC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • Looking at the Profit Margin, with a value of 8.58%, CDXC is in the better half of the industry, outperforming 74.55% of the companies in the same industry.
  • CDXC has a better Operating Margin (7.76%) than 63.64% of its industry peers.
  • With an excellent Gross Margin value of 61.84%, CDXC belongs to the best of the industry, outperforming 87.27% of the companies in the same industry.
  • In the last couple of years the Gross Margin of CDXC has grown nicely.
Industry RankSector Rank
OM 7.76%
PM (TTM) 8.58%
GM 61.84%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
CDXC Yearly Profit, Operating, Gross MarginsCDXC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CDXC is creating some value.
  • CDXC has more shares outstanding than it did 1 year ago.
  • CDXC has more shares outstanding than it did 5 years ago.
  • CDXC has a better debt/assets ratio than last year.
CDXC Yearly Shares OutstandingCDXC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CDXC Yearly Total Debt VS Total AssetsCDXC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • CDXC has an Altman-Z score of 15.46. This indicates that CDXC is financially healthy and has little risk of bankruptcy at the moment.
  • CDXC has a better Altman-Z score (15.46) than 100.00% of its industry peers.
  • CDXC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 15.46
ROIC/WACC1.11
WACC10.97%
CDXC Yearly LT Debt VS Equity VS FCFCDXC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • CDXC has a Current Ratio of 3.57. This indicates that CDXC is financially healthy and has no problem in meeting its short term obligations.
  • CDXC has a Current ratio (3.57) which is comparable to the rest of the industry.
  • A Quick Ratio of 3.06 indicates that CDXC has no problem at all paying its short term obligations.
  • CDXC has a Quick ratio (3.06) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.57
Quick Ratio 3.06
CDXC Yearly Current Assets VS Current LiabilitesCDXC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 242.86% over the past year.
  • CDXC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.17%.
  • CDXC shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.56% yearly.
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%

3.2 Future

  • Based on estimates for the next years, CDXC will show a very strong growth in Earnings Per Share. The EPS will grow by 43.55% on average per year.
  • CDXC is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 19.24% yearly.
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CDXC Yearly Revenue VS EstimatesCDXC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
CDXC Yearly EPS VS EstimatesCDXC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 78.70, the valuation of CDXC can be described as expensive.
  • The rest of the industry has a similar Price/Earnings ratio as CDXC.
  • CDXC's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 27.27.
  • The Price/Forward Earnings ratio is 66.13, which means the current valuation is very expensive for CDXC.
  • The rest of the industry has a similar Price/Forward Earnings ratio as CDXC.
  • CDXC's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.16.
Industry RankSector Rank
PE 78.7
Fwd PE 66.13
CDXC Price Earnings VS Forward Price EarningsCDXC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 61.82% of the companies in the same industry are more expensive than CDXC, based on the Enterprise Value to EBITDA ratio.
  • 65.45% of the companies in the same industry are more expensive than CDXC, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 51.22
EV/EBITDA 66.44
CDXC Per share dataCDXC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of CDXC may justify a higher PE ratio.
  • CDXC's earnings are expected to grow with 43.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.14
PEG (5Y)N/A
EPS Next 2Y41.63%
EPS Next 3Y43.55%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CDXC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CHROMADEX CORP

NASDAQ:CDXC (3/18/2025, 8:00:02 PM)

After market: 7.87 0 (0%)

7.87

-0.07 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-04
Earnings (Next)05-06
Inst Owners30.29%
Inst Owner Change-0.24%
Ins Owners0.01%
Ins Owner Change0%
Market Cap611.89M
Revenue(TTM)99.60M
Net Income(TTM)8.55M
Analysts84.44
Price Target9.21 (17.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)415%
Min EPS beat(2)341.18%
Max EPS beat(2)488.82%
EPS beat(4)4
Avg EPS beat(4)242.8%
Min EPS beat(4)41.19%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)150.17%
EPS beat(12)10
Avg EPS beat(12)102.99%
EPS beat(16)12
Avg EPS beat(16)74.16%
Revenue beat(2)2
Avg Revenue beat(2)6.44%
Min Revenue beat(2)6.07%
Max Revenue beat(2)6.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-9.39%
Max Revenue beat(4)6.81%
Revenue beat(8)4
Avg Revenue beat(8)1.29%
Revenue beat(12)4
Avg Revenue beat(12)-1.38%
Revenue beat(16)5
Avg Revenue beat(16)-2.29%
PT rev (1m)17.21%
PT rev (3m)17.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.77%
EPS NY rev (3m)-2.77%
Revenue NQ rev (1m)-1.81%
Revenue NQ rev (3m)-1.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 78.7
Fwd PE 66.13
P/S 6.14
P/FCF 51.22
P/OCF 50.53
P/B 13.27
P/tB 13.38
EV/EBITDA 66.44
EPS(TTM)0.1
EY1.27%
EPS(NY)0.12
Fwd EY1.51%
FCF(TTM)0.15
FCFY1.95%
OCF(TTM)0.16
OCFY1.98%
SpS1.28
BVpS0.59
TBVpS0.59
PEG (NY)4.14
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 12.52%
ROE 18.55%
ROCE 15.35%
ROIC 12.13%
ROICexc 104.84%
ROICexgc 111.73%
OM 7.76%
PM (TTM) 8.58%
GM 61.84%
FCFM 11.99%
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.46
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 20.02%
Cap/Sales 0.16%
Interest Coverage 7726
Cash Conversion 141.79%
Profit Quality 139.72%
Current Ratio 3.57
Quick Ratio 3.06
Altman-Z 15.46
F-Score7
WACC10.97%
ROIC/WACC1.11
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A
EBIT growth 1Y237.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year538.3%
EBIT Next 3Y140.93%
EBIT Next 5YN/A
FCF growth 1Y71.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.14%
OCF growth 3YN/A
OCF growth 5YN/A

CHROMADEX CORP / CDXC FAQ

What is the fundamental rating for CDXC stock?

ChartMill assigns a fundamental rating of 6 / 10 to CDXC.


Can you provide the valuation status for CHROMADEX CORP?

ChartMill assigns a valuation rating of 4 / 10 to CHROMADEX CORP (CDXC). This can be considered as Fairly Valued.


Can you provide the profitability details for CHROMADEX CORP?

CHROMADEX CORP (CDXC) has a profitability rating of 6 / 10.


Can you provide the financial health for CDXC stock?

The financial health rating of CHROMADEX CORP (CDXC) is 8 / 10.


What is the expected EPS growth for CHROMADEX CORP (CDXC) stock?

The Earnings per Share (EPS) of CHROMADEX CORP (CDXC) is expected to grow by 19% in the next year.